Fig. 5
From: Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy
Changes in the body weights of the rats (A) and mice (D) and changes in the tumor volumes of the C6 glial cells (B) and PANC-1 cells (E) after intratumoral administration (Tumor size at the time of administration and the 211At dose were 334 ± 152 mm3 and 1.4 ± 0.4 MBq/tumor for rats and 72 ± 11 mm3 and 1.2 ± 0.1 MBq/tumor for mice, respectively). The C6 glial (C) and PANC-1 (F) tumors were excised 40 days after administration and their masses were measured. The error bars indicate the standard deviation. The tumor mass after the administration of 211At was significantly smaller than that seen in the controls. In PANC-1 xenografts, necrosis inside the tumor increased the size variability, leading to an increased standard deviation. The body weights of the mice in the control group were significantly lower than those in the group treated with 211At (*0.01 ≤ p < 0.05, **0.001 ≤ p < 0.01, ***p < 0.001)